ENTELLUS MEDICAL, INC. (NASDAQ:ENTL) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
Entellus Medical, Inc. (Entellus) held its Annual Meeting of
Stockholders (the Annual Meeting) on June13, 2017. At the Annual
Meeting, Entelluss stockholders considered two proposals, each of
which is described in more detail in Entelluss definitive proxy
statement filed with the Securities and Exchange Commission on
April26, 2017.
As of the close of business on April17, 2017, the record date for
the Annual Meeting, there were 21,916,416 shares of Entellus
common stock outstanding and entitled to vote at the Annual
Meeting. Each share of Entellus common stock was entitled to one
vote. Stockholders holding an aggregate of 19,681,419 shares of
Entellus common stock entitled to vote at the Annual Meeting,
representing 89.8% of the outstanding shares of Entellus common
stock as of the record date, and which constituted a quorum
thereof, were present in person or represented by proxy at the
Annual Meeting.
The final results of such stockholder voting on each proposal
brought before the Annual Meeting are set forth below:
| ProposalNo.1 |
The two directors nominees proposed by the Board of Directors of Entellus were elected to serve as members of the Board of Directors, each to serve a term of three years ending at the 2020 Annual Meeting of Stockholders or until his successor has been duly elected or qualified, by the following final voting results: |
| VotesFor | VotesWithheld | BrokerNon-Votes | ||||
| JoshuaBaltzell | 13,907,981 | 2,350,444 | 3,422,994 | |||
| ShawnMcCormick | 15,075,887 | 1,182,538 | 3,422,994 |
| ProposalNo.2 |
The ratification of the appointment of Grant Thornton LLP as Entelluss independent registered public accounting firm for the year ending December31, 2017 was approved by the following final voting results: |
|
VotesFor |
VotesAgainst |
VotesAbstained |
BrokerNon-Votes |
|||
| 19,588,674 | 90,762 | 1,983 |
Regarding Entelluss other directors, (i)each of Brian E. Farley
and Guido Neels continue to serve as a director for a term ending
at Entelluss 2018 Annual Meeting of Stockholders; and (ii)each of
John K. Bakewell, David B. Milne and Robert S. White continue to
serve as a director for a term ending at Entelluss 2019 Annual
Meeting of Stockholders.
About ENTELLUS MEDICAL, INC. (NASDAQ:ENTL)
Entellus Medical, Inc. is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation. The Company’s XprESS family of products is used to treat patients with inflammation of the frontal, ethmoid, sphenoid and maxillary sinuses. Its XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The Company’s PathAssist tools provide ENT physicians with a way to confirm sinus location and XprESS device placement. Its FocESS Sinuscopes provide ENT physicians with a solution for endoscopic visualization during a sinus procedure.
